Angiotensin II type 1 receptor blockers: Class effects versus molecular effects

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 12, Issue 1, 2011, Pages 1-7

  Miura, Shin Ichiro ^a,b   Karnik, Sadashiva S ^b   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

angiotensin II receptor blockers; angiotensin II type 1 receptor; class effects; common molecular structures; molecular effects

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ADIPONECTIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CANDESARTAN; CARBOXYL GROUP; CHEMOKINE RECEPTOR CCR2; ENALAPRIL; EPROSARTAN; G PROTEIN COUPLED RECEPTOR; GLUCOSE; IMIDAZOLE DERIVATIVE; INTERLEUKIN 6; INTERLEUKIN 8; IRBESARTAN; LOSARTAN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANTIINFLAMMATORY AGENT; URIC ACID;

ANTIINFLAMMATORY ACTIVITY; ARTERY CONSTRICTION; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CHEMICAL STRUCTURE; CLINICAL ASSESSMENT; CLINICAL STUDY; CORONARY ARTERY CONTRACTION; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART LEFT VENTRICLE MASS; HUMAN; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTENOSIS; REVIEW; RISK REDUCTION; THROMBOCYTE ACTIVATION; URIC ACID BLOOD LEVEL; ANIMAL; BLOOD; CHEMISTRY; CLASSIFICATION; COMPARATIVE STUDY; INVERSE AGONISM; METABOLISM;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG INVERSE AGONISM; HUMANS; RECEPTOR, ANGIOTENSIN, TYPE 1; URIC ACID;

EID: 79952564650     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320310370852     Document Type: Review

References (48)

1. de Gasparo M, Catt KJ, Inagami T, et al. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
2. Miura S, Fujino M, and Saku K. Angiotensin II receptor blocker as an inverse agonist: a current perspective. Curr Hypertens Rev 2005; 1: 115-121.
3. Noda K, Saad Y, Kinoshita A, et al. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem 1995;270: 2284-2289.
4. Feng YH, Noda K, Saad Y, et al. The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism. J Biol Chem 1995; 270: 12846-12850.
5. Noda K, Saad Y, Karnik SS, et al. Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. J Biol Chem 1995; 270: 28511-28514. (Pubitemid 3016801)
6. Feng, YH, Miura S, Husain A, et al. Mechanism of constitutive activation of the AT1 receptor: influence of the size of the agonist switch binding residue Asn(111). Biochemistry 1998; 37: 15791-15798. (Pubitemid 28524750)
7. Miura S, Feng YH, Husain A, et al. Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. J Biol Chem 1999; 274: 7103-7110.
8. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251. (Pubitemid 23191415)
9. Tuccinardi T, Calderone V, Rapposelli S, and Martinelli A. Proposal of a new binding orientation for non-peptide AT1 antagonists: homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis. J Med Chem 2006; 49: 4305-4316. (Pubitemid 44036674)
10. Fabia MJ, Abdilla N, Oltra R, Fernandez C, and Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25:1327-1336. (Pubitemid 46924066)
11. Oparil S, Williams D, Chrysant SG, Marbury TC, and Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283-291, 318.
12. Kivlighn SD, Zingaro GJ, Gabel RA, et al. In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors. Eur J Pharmacol 1995;294: 439-450. (Pubitemid 26016754)
13. Zhang J, Pfaffendorf M, Zhang JS, and Van Zwieten PA. A non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations. Eur J Pharmaco. 1994; 252: 337-340. (Pubitemid 24053705)
14. Shibouta Y, Inada Y, Ojima M, et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H- tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole- 7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1Htetrazol- 5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993; 266: 114-120.
15. Le MT, Pugsley MK, Vauquelin G, and Van Liefde I. Molecular characterization of the interactions between olmesartan medoxomil and telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol 2007; 151: 952-962. (Pubitemid 47195538)
16. Seifert R, Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 381-416. (Pubitemid 35251788)
17. Miura S, Kiya Y, Kanazawa T, et al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol 2008; 22:139-146.
18. Miura S, Fujino M, Hanzawa H, et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 2006; 281: 19288-19295. (Pubitemid 44035433)
19. Morisset S, Rouleau A, Ligneau X, et al. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 2000; 408: 860-864. (Pubitemid 32016096)
20. Kijima K, Matsubara H, Murasawa S, et al. Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes. Circ Res 1996; 79: 887-897. (Pubitemid 26317839)
21. Yasuda N, Miura S, Akazawa H, et al. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep 2008; 9: 179-186. (Pubitemid 351223456)
22. Zou Y, Akazawa H, Qin Y, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004; 6: 499-506. (Pubitemid 38786592)
23. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 1996; 156: 1789-1796.
24. Pitt B, Poole-Wilson PA, Segal R, et al. Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the losartan heart failure survival study - ELITE II. Lancet 2000; 355: 15822-15827.
25. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766. (Pubitemid 37093915)
26. Hernandez-Presa M, Bustos C, Ortego M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kB activation, monocyte chemoattractant protein-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95: 1532-1541. (Pubitemid 27142812)
27. Proudfoot JM, Croft KD, Puddey IB, and Beilin LJ. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor- stimulated human monocyte chemoattractant protein-1. J Pharmacol Exp Ther 2003; 305: 846-853. (Pubitemid 36617960)
28. Clasen R, Schupp M, Foryst-Ludwig A, et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137-143. (Pubitemid 40946504)
29. Marshall TG, Lee RE, and Marshall FE. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model 2006; 3: 1.
30. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004; 64: 2537-2565. (Pubitemid 39591650)
31. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81. (Pubitemid 36842239)
32. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-3692. (Pubitemid 39665258)
33. Schupp M, Janke J, Clasen R, Unger T, and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057. (Pubitemid 38620211)
34. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002. (Pubitemid 38579904)
35. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
36. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
37. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
38. Iwanaga T, Sato M, Maeda T, Ogihara T, and Tamai I. Concentration- dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 2007; 320: 211-217. (Pubitemid 46025736)
39. Picca M, Agozzino F, and Pelosi G. Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. Adv Ther 2004; 21: 76-86. (Pubitemid 38988471)
40. Pool JL, Guthrie RM, Littlejohn TW 3rd, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-tomoderate hypertension. Am J Hypertens 1998; 11: 462-470. (Pubitemid 28231459)
41. Krämer C, Sunkomat J, Witte J, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 90: 770-776. (Pubitemid 34633892)
42. Pantev E, Stenman E, Wackenfors A, Edvinsson L, and Malmsjo M. Comparison of the antagonistic effects of different angiotensin II receptor blockers in human coronary arteries. Eur J Heart Fail 2002; 4: 699-705. (Pubitemid 35403077)
43. Iwata A, Miura S, Imaizumi S, et al. Do valsartan and losartan have the same effects in the treatment of coronary artery disease? Circ J 2007; 71: 32-38. (Pubitemid 46045547)
44. Sugihara M, Miura S, Takamiya Y, et al. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res 2009; 32: 625-630.
45. Yamada S, Ano N, Toda K, et al. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. Hypertens Res 2008; 31: 601-606. (Pubitemid 351772849)
46. Nunez A, Gomez J, Zalba LR, et al. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst 2000; 1: 175-179.
47. Nakayama S, Watada H, Mita T, et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008; 31: 7-13. (Pubitemid 351325609)
48. Sasaki T, Noda Y, Yasuoka Y, et al. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome. Hypertens Res 2008; 31: 921-929. (Pubitemid 351895037)